Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Swedish Orphan Biovitrum AB ( (SE:SOBI) ).
Swedish Orphan Biovitrum AB’s Board of Directors has decided to repurchase class C shares to fulfill commitments under its long-term incentive programs. This move, authorized by the Annual General Meeting, aims to convert these shares into common shares, increasing the total number of common shares held by the company.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Sobi is a global biopharma company dedicated to transforming the lives of individuals with rare diseases through innovative solutions. With approximately 1,900 employees worldwide, Sobi operates across Europe, North America, the Middle East, Asia, and Australia. In 2024, the company reported revenues of SEK 26 billion, and its shares are listed on Nasdaq Stockholm.
Average Trading Volume: 325,985
Current Market Cap: SEK98.16B
See more insights into SOBI stock on TipRanks’ Stock Analysis page.